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ABSTRACT
INTRODUCTION: While animal studies consistently show a preventive role of
statin use in colon cancer development, evidence from human studies is conflicting
with recent reports suggesting an increased risk of aberrant crypt foci and
adenoma. We hypothesize that insufficient control of confounding due to indication
bias for prescribing of statins, particularly obesity-induced physiologic
dysregulation, might partly explain discrepant results. METHODS: We analyzed
data from patients receiving standard colonoscopy at the Colon Cancer Prevention
Program of the University of Connecticut Health Center, which was followed by
chromoendoscopy for ACF detection. ACF number was categorized at low (<10) or
high (≥10). We calculated Univariate, Age-Adjusted and Multivariate Logistic
Regression to estimate Odds Ratios (ORs) and 95% Confidence Intervals (CIs) for
high ACF number in relation to regular statin use (i.e., ≥ 1 pill per week for the past
12 months). Adiposity measures of Body Mass Index (BMI), Waist-Hip-Ratio
(WHR) and Waist Circumference (WC) were added separately in the multivariate
model as surrogates to assess indication bias. A composite variable was created
to assess the impact of individual compared to joint regular use of statins and
aspirin (baby and/or full dose) on ACF number. RESULTS: Participants who
reported regular use of statins had a higher mean ACF number than participants
who reported taking <1 pill per week (17.20 vs. 9.02, respectively, p=0.001). The
mean age for the high ACF group was greater than the mean age for the low ACF
group (59.40 versus 54.17 years, respectively, p=0.002). Never and past smokers
were more likely to have low ACF than current smokers (58.9% vs. 60.0% vs.
18.2%, respectively, p=0.037). Univariate logistic regression showed that patients
who regularly took statins were 3.9 (95%CI=1.43-10.74) times more likely to have a
high ACF count than those not taking statins regularly, which was reduced to 2.67
(95%CI=0.89-7.97) in the age-adjusted analysis. In the basic multivariate model,
the OR for high ACF among regular statin users was 1.47 (95%CI=0.28-7.74) in
comparison to patients who consumed 1 or fewer pills per week. When adiposity
measures were added into the basic multivariate model, the ORs for high ACF
were: 1.24 for BMI (95%CI=0.21-7.47; p=0.017); 0.68 for WHR (95%CI=0.10-5.40;
p=0.702); and 1.20 for WC (95%CI=0.20-1.20; p=0.842). Compared to taking
neither aspirin nor statins (referent group), univariate ORs were: 15.0
(95%CI=1.55-145.23) for taking statins only on a regular basis; 1.83 (95%CI=0.595.68) for regular use of aspirin only; and 4.29 (95%CI=1.24-14.83) for regular use
of both statins and aspirin. OR estimates were slightly attenuated in age-adjusted
analyses and were substantially reduced in multivariate analyses, and no longer
statistically significant. CONCLUSIONS: While regular statin use in our study
population was associated with a statistically significant higher ACF count in
univariate analyses, this effect did not remain after controlling for key risk factors
for colon cancer. It is possible that prior evidence of an adverse role of statin use
in colorectal neoplasia in human studies may be explained in part by confounding.
Our results must be interpreted with caution due to small numbers in study groups.

v

1.0 INTRODUCTION

1.1 Established Risk Factors for Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related
mortality for both men and women in the United States with over 50,000 deaths
reported in 2007 alone (CDC, 2012). Incidence rates of CRC in the United
States, however, have been decreasing recently in both males and females
(Jemal et al., 2011), over the past two decades, largely due to detection and
removal of precancerous lesions through CRC screening.
Regular use of aspirin and other non-steroidal anti-inflammatory drugs
(NSAIDs) has been reported to reduce the primary occurrence of adenomas
and contribute to their regression (Stevens et al., 2006). Regular aspirin use
has been associated with a reduced risk of CRC as well (Potter, 1999). Two
proposed mechanisms linking CRC pathogenesis are insulin resistance and
chronic inflammation (Bruce et al., 2000; Kaaks et al., 2000; Potter, 1999;
Stevens et al., 2006). Adiposity-induced insulin resistance is thought to be the
pathway linking surplus body fat with colon cancer risk (Swede et al., 2009). A
study by Swede et al. (2009) found that a relatively high level of visceral fat
was associated with increased ACF. Together, this, and the chronic
inflammation model provide a framework from which a large portion of CRC
etiology and epidemiology can be interpreted (Stevens et al., 2006).
1

Modifiable risk factors for CRC also include smoking, physical inactivity,
and dietary intake (Jemal et al., 2011). Diet is thought to influence 70-90% of
CRC (Lipkin et al., 1999). While the mechanism through which diet influences
CRC is not well understood, it is thought that the increased consumption of red
meat, and possibility the low intake of fiber, including fruits and vegetables,
increases CRC risk (Stevens et al., 2006). Additionally, lack of physical activity
and obesity are associated with increased risk of CRC (Stevens et al., 2006).

1.2 Statins and Colorectal Cancer: Unclear Evidence

As noted above, anti-inflammatory agents, such as aspirin, are thought to be
preventive for CRC and possibly ACF. Another class of drugs, statins, has
been examined for a possible preventive role in CRC but human evidence
remains inconsistent. Statins, which are HMG-CoA inhibitors, are among the
most commonly prescribed drugs worldwide for their cholesterol-lowering
properties (Boudreau et al, 2010). Their use has dramatically risen in the past
decade and is likely to continue rising (Boudreau et al., 2010). It is estimated
that 1 out of every 10 adults in the U.S. population is on statins to reduce
circulating lipoprotein levels and to consequently decrease their risk for
cardiovascular disease (Ahnen & Byers, 2009). There are currently six statins
on the U.S. market: lovastatin, pravastatin, simvastatin, fluvastatin,
atorvastatin, and rosuvastatin.
2

Statins inhibit HMG-CoA reductase, a major rate-limiting enzyme of the
mevalonate pathway, thereby preventing the conversion of HMG-CoA to
mevalonate (Boudreau et al., 2010). This results in decreased levels of
mevalonate and its subsequent products (Boudreau et al., 2010). Many
products of the mevalonate pathway are vital for proper cellular functions,
including membrane integrity, cell signaling, protein synthesis, and cell cycle
progression (Boudreau et al., 2010). Inhibition of the mevalonate pathway may
disrupt these processes in neoplastic cells, resulting in control of tumor
initiation, growth, and metastasis (Boudreau et al., 2010). Statins have many
biologically plausible effects on cancer risk (Ahnen & Byers, 2009) from
affecting protein synthesis to angiogenesis, apoptosis, cellular immunity, and
cancer metastasis (Ahnen & Byers, 2009). Many studies demonstrate statininduced programmed cell death, or apoptosis, in several cell lines, including
mammary carcinoma, lung, colorectal, pancreatic, and prostrate carcinoma
(Boudreau et al., 2010).
The initial evidence of a role in CRC came from animal studies, which
suggested that statins could have chemopreventive properties (Agarwal et al.,
1999). Epidemiological studies have also suggested that statins play a role in
CRC. For example, two large randomized control trials showed decreases in
the risk for CRC among those randomized to take statins by 19% and 43%
(Ahnen & Byers, 2009). These reductions were not statistically significant,
however, and were secondary endpoints in trials originally conducted for other
3

purposes (Ahnen & Byers, 2009). Nevertheless, this paved way for a large
number of observational case-control and cohort studies examining the
relationship between statins and CRC (Ahnen & Byers, 2009).
Several case-control and cohort studies have found no association
between statin use and CRC risk, while two large observational studies
reported a 35-43% reduction in CRC among statin users compared to nonusers (Boudreau et al., 2010). In a population-based cohort study, Singh et al.
assessed the effect of the long-term regular use of statins on the risk of CRC
(2009). They reported no statistically significant reduction in CRC risk with
regular use of statins, irrespective of the duration or dose (Singh et al., 2008).
Singh et al. also found a small increased risk of CRC associated with low dose
statin use (Singh et al., 2008). Statins have been shown to have a stimulatory
effect on some CRC cell lines (Singh et al., 2008).
In a cohort of male veterans undergoing surveillance colonoscopy,
Parker-Ray et al. (2010) reported that statin use did not decrease the risk for or
number of adenomatous polyps. The number of polyps that were found on the
index colonoscopy was the only factor that was associated with adenoma
recurrence (Parker-Ray et al., 2010). Age, BMI, and number of polyps
detected at index colonoscopy were found to be positively associated with the
number of polyps detected at follow-up colonoscopy (Parker-Ray et al., 2010).
Diabetes and non-Hispanic white race was found to be inversely associated
with the number of polyps detected at follow-up colonoscopy (Parker-Ray et
4

al., 2010). The use of statins was not protective against the recurrence of
adenomatous polyps (Parker-Ray et al., 2010). Currently, there is no
convincing evidence to support prescribing statins for the chemoprevention of
colorectal neoplasia.

1.3 Aberrant Crypt Foci

Colonic intestinal epithelium is rapidly renewing tissue, due to the loss of cells
during the final stage of the digestive process, which is marked by homeostatic
equilibrium between cellular proliferation and abatement (Lopez-Ceron &
Pellise, 2011). Aberrant crypt foci (ACF) are pre-polyp abnormalities identified
in single crypts detected by high magnification chromendoscopy (Stevens et
al., 2006) using dye (e.g., indigo carmine). ACF consist of large, thick crypts in
the colon, first identified in mice treated with azoxymethane (Bird, 1987). ACF
were also reported in the colonic mucosa of humans (Takayama et al., 1998).
Histologically, ACF can be classified as hyperplastic or dysplastic
(Lopez-Ceron & Pellise, 2011). Hyperplastic ACF are the most common type
and consist of larger and longer crypts with apical branching and serration
(Lopez-Ceron & Pellise, 2011). Dysplastic ACF are less common, but are
more frequent in Eastern than Western populations and are composed of
smaller, non-serrated crypts (Lopez-Ceron & Pellise, 2011). In most instances,
ACF are defined as a cluster of crypts that stain darker than their surrounding
5

mucosa in addition to one of the following characteristics: crypts with larger
diameters than surrounding mucosa, thicker epithelial linking, dilated crypt
lumen, or a slightly raised appearance (Lopez-Ceron & Pellise, 2011).

1.4 Clinical Utility of ACF

Data on ACF prevalence range from 15% to 77% in healthy individuals and
80% to 100% in patients with colorectal neoplasms (Lopez-Ceron & Pellise,
2011). ACF are thought to increase in size by a dynamic process known as
crypt fission, although this mechanism is not well understood (Lopez-Ceron &
Pellise, 2011).
Colonic ACF may be predictive markers of future risk of CRC (Stevens
et al., 2006). ACF are the earliest identifiable morphological change in the
pathway to CRC, according to Kinzler and Vogelstein (1996). Both
morphologically and genetically distinct, ACF may be precursors of adenoma
and cancer. It has been shown, however, that ACF are a heterogeneous group
of lesions, and while some may be important in CRC development, others are
not (Stevens et al., 2006).
The number, size, and lumen morphology of ACF have been correlated
with CRC risk (Lopez-Ceron & Pellise, 2011). The total number and density
(number/cm2) of ACF in the rectum tend to be representative of the amount of
ACF present elsewhere in the colon (Lopez-Ceron & Pellise, 2011).
6

Accordingly, most endoscopic studies focus on rectal ACF (Lopez-Ceron &
Pellise, 2011). Crypt multiplicity, the number of crypts per focus, is correlated
with ACF size (Lopez-Ceron & Pellise, 2011). Studies have shown that as age
increases, ACF size increases (Lopez-Ceron & Pellise, 2011). Still, ACF size
and risk of CRC are not clear (Lopez-Ceron & Pellise, 2011). A recent study
showed that small ACF were associated with distal adenomas (Lopez-Ceron &
Pellise, 2011). While some reports have shown an association between the
shape of the lumen and dysplasia, other studies have found no correlation
between the two (Lopez-Ceron & Pellise, 2011).
The progression of CRC is a very lengthy process that can span up to
two decades (Alrawi et al., 2006). Intervention by polyp removal has now
become a standard of clinical care (Alrawi et al., 2006). Understanding the
pathology of the colonic crypt can provide insight into the mechanisms of
malignant transformation and could be key to identifying populations at
increased risk of CRC and providing them with better preventative care
measures (Alrawi et al., 2006).
In a study by Sakai et al. (2011), significant stepwise increments in both
prevalence and number of ACF were observed from normal to adenoma to
CRC cases. Mean number of ACF was also found to be significantly higher in
the subject group with advanced adenoma than in the subject group with nonadvanced adenoma (Sakai et al., 2011). These results indicate that ACF may
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serve as a reliable biomarker of human colorectal carcinogenesis (Sakai et al.,
2011).
ACF also harbor genetic and epigenetic alterations that can be detected
in early neoplastic lesions and CRC (Lopez-Ceron & Pellise, 2011). For
example, mutations in the adenomatous polyposis coli (APC) gene have been
strongly associated with dysplastic changes in ACF (Lopez-Ceron & Pellise,
2011). As a result, patients with familial adenomatous polyposis present with a
high occurrence of dysplastic ACF (Lopez-Ceron & Pellise, 2011). Conversely,
a small proportion of dysplastic ACF show APC mutations in sporadic CRC
while there is no evidence that hyperplastic ACF have this mutation (LopezCeron & Pellise, 2011).
CRC carcinogenesis can also occur through microsatellite instability
(MSI), a condition that results from defects in the normal DNA repair process
due to the inactivation of certain genes, such as MLH1, MSH2, MSH6, or
PMS2 (Lopez-Ceron & Pellise, 2011). This inactivation can be either inherited
(e.g., Lynch Syndrome) or acquired (e.g., MLH1 Promoter methylation) (LopezCeron & Pellise, 2011). Fifteen percent of sporadic CRC is associated with
MSI, and this frequency increases from ACF to adenoma to carcinoma (LopezCeron & Pellise, 2011). Almost all patients with Lynch Syndrome present with
ACF that show MSI (Lopez-Ceron & Pellise, 2011). One study reported that a
high concentration of MSI is found in adenomas of patients with Lynch
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Syndrome, and 100% of ACF in these patients exhibited MSI (Lopez-Ceron &
Pellise, 2011).
An alternative pathway to the development of CRC, known as the
serrated pathway, suggests the development of cancer without classic
adenoma, but rather from serrated lesions related to hyperplastic polyps
(Lopez-Ceron & Pellise, 2011). Serrated lesions are thought to occur as a
result of DNA modifications not related to modifying the basic structure of
genes (Lopez-Ceron & Pellise, 2011). The best-known epigenetic mechanism
of CRC results from the inactivation of the hypermethylation of the promoter
region of tumor suppressor genes (Lopez-Ceron & Pellise, 2011).
ACF, while relatively common, in normal individuals, continue to be
investigated as the earliest precursors of adenomas and cancers (Alrawi et al.,
2006). While most ACF do not progress on to become cancerous, with some
even regressing or disappearing, it is likely that certain factors induce them to
become malignant (Alrawi et al., 2006). The histomorphologic and/or genetic
changes in ACF that lead to their potential role in neoplastic progression are
still not well understood. Studies on murine models have demonstrated that
genetic cluster analyses are useful in identifying which murine ACF are high
risk to go on to undergo malignant transformation (Alrawi et al., 2006).
Alrawi et al. (2006) examined whether genomic instabilities exist in ACF
from the normal, non-inflammatory setting. Inter-(simple sequence repeat)
PCR was used to quantify the genomic damage present in each ACF sample.
9

Even single base pair insertions or deletions can be identified through this
technique (Alrawi et al., 2006). Generally, however, detected genetic
anomalies are found to be larger (Alrawi et al., 2006). ACF from the same
patient were observed to each have unique genomic fingerprints (Alrawi et al.,
2006). Additionally, one-fourth of the thirty-two ACF examined revealed
moderate instability after inter-PCR (Alrawi et al., 2006). The results of this
study indicate that ACF characterization could become a valuable clinical
screening tool to identify those individuals that are more likely to develop
colorectal carcinoma from instable ACF.

1.5 Risk Factors of ACF

There are many factors thought to influence the natural history of ACF.
Takayama et al. (1998) found that the prevalence and number of ACF
increased abruptly between the ages of 40 and 50, and patients with cancer
had a consistently higher prevalence and number of ACF, regardless of age.
Patients on low dose aspirin have been shown to have lower prevalence of
ACF, and lower prevalence of ACF have been reported in patients taking
NSAIDs as well (Lopez-Ceron & Pellise, 2011). These results have not been
consistent, however. Tobacco has been shown to be one agent that increases
number of ACF in most studies (Lopez-Ceron & Pellise, 2011) and is an
important risk factor for colorectal neoplasia (Anderson et al., 2010).
10

Alcohol is thought to induce ACF as well (Lopez-Ceron & Pellise, 2011), but
the effects of different types of alcoholic beverages (e.g. beer, liquor, wine) are
not well understood (Lopez-Ceron & Pellise, 2011).

1.6 Conclusion

There is growing evidence that statins may increase ACF number in humans,
and that ACF may be precursor lesions of CRC, but much remains to be
understood. ACF are an efficient way to study this issue, but the role of statins
in CRC development, with ACF as an intermediate, is still uncertain. Indication
bias due to adiposity could be at play here since statins could be prescribed to
people who are more likely to be overweight and obese. As such, these
people may be at increased risk for high ACF count and subsequent CRC
development. This research project will incorporate adiposity measures and a
wider range of circulating biomarkers in order to use ACF to provide insight into
the role of statins in CRC. It is thought that patients on statins will have a
higher number of ACF than those not on statins, but this association will lessen
once controlling for adiposity. Using data from a pool of patients who received
a standard colonoscopy at the Colon Cancer Prevention Program at the
University of Connecticut Health Center, this investigation aims to:
1.

Determine the association between statin use and ACF
number, controlling for key risk factors for CRC, and
11

2.

Assess if the relationship between statin use and ACF count
may be modified by controlling for different measures of
adiposity (body mass index [BMI], waist circumference [WC],
and waist-hip-ratio [WHR]).

12

2.0 METHODS

2.1 Study Population

We obtained data from 101 patients receiving standard colonoscopy at the
Colon Cancer Prevention Program of the University of Connecticut Health
Center from February 2010 to November 2011. Patients attended the clinic for
routine screening or surveillance following the detection of a pathological
finding at a previous exam. The goal of the clinic-based ACF study is to
identify and describe the clinical importance of ACF and the epidemiologic risk
factors for and molecular features of ACF and other early colonic neoplasia. A
total of 14 people were excluded because they were underweight (BMI < 18.5)
or were missing adiposity measurements.

2.2 Patient Data

An Advanced Practice Nurse Practitioner (APRN) took measurement of height,
weight, hip (i.e., widest torso circumference), and waist (i.e., narrowest torso
circumference as defined in Gram et al. (2006). A fasting blood sample (three
heparinized vials at 10 ml) was drawn from the intravenous line at the
colonoscopy exam and transported to the research laboratory. Samples were
separated into 0.5 ml aliquots and frozen at -80°C. Patients were also
13

questioned about medication use, family history, personal history, and lifestylebehavior questions (e.g., tobacco and alcohol use).

2.3 Colonoscopy Procedures and ACF Detection

All patients in the study underwent routine colonoscopy for clinical purposes.
Prior to the clinic visit, colon preparation was performed with a magnesium
citrate based prep. ACF detection, performed after the colonoscopy, lasted for
up to 30 minutes. High definition colonoscopes (Olympus PCF-H180AL and
CFH-180AL) were utilized for examination purposes. Close focus properties
allowed for clear, detailed observations.
The distal 20 cm-section of colon, including the rectum, were washed.
This was followed by water wash to remove mucous, after which examination
was performed. In order to visualize the colon, a fresh solution of indigo
carmine 0.8% was prepared and applied for contrast staining using spray
catheters. The dye was allowed to absorb for two minutes before endoscopy
was performed. A finding of an ACF is accepted if two or more crypts are
darkly stained and have lumen diameters that are 1.5-2.0 times those of
surrounding crypt lumens under close magnification.
ACF were also required to be raised above the mucosal level. The
requirements of being round, dilated, slit, or having a star-shaped lumen or
thick crypt wall with compressed lumen were necessary to confirm
14

identification. The colon was divided into four quadrants or the scope was
withdrawn in a clockwise fashion as techniques to ensure that the ACF were
not double-counted or missed. Narrow-band imaging (NBI), which is a non-dye
imaging technique that enhances mucosal and vascular detail, was used to
detect ACF in some patients.
The variability of the raters was addressed by including the requirement
that the raters be trained in ACF determination and confer and reach an
agreement on the determination of an ACF finding at the time of
chromoendoscopy. In the 20-cm distal region of the colon, ACF were counted
and digital images were captured. A maximum of 10 biopsy specimens of ACF
were taken within the distal 20 cm using forceps (Precisor EXL, CR Bard). A GI
pathologist (TVR), who was unbiased concerning the clinical findings, analyzed
coded specimens of frozen section of ACF that had been stained with H&E
(hematoxylin and eosin stain). Histologic analysis was performed using light
microscopy.

2.4 Variables

The number of ACF was categorized into two groups (<10, ≥10), termed low
ACF and high ACF. The median number of ACF was 9 and therefore, our
outcome was having <10 or ≥10 ACF.

15

Statins were divided into <1 pill per week or ≥1 pill per week (regular
use) in past 12 months. Use of medications other than statins, including baby
aspirin, aspirin, and other NSAIDs, were divided into never, <1 pill per week,
or ≥ 1 pill per week. In the logistic regression, these variables were split into
two categories: <1 pill per week and ≥1 pill per week. This was done to ensure
no cell counts were too small.
Biomarkers were analyzed as continuous variables. BMI, WHR, WC,
and age were analyzed as continuous variables as well as categorical. The
following groups defined categories of BMI for use in descriptive analysis:
Normal (18.5–24.9), Overweight (25.0–29.9), Obese I (30.0–34.9), Obese II
(35.0–39.9), and Obese III (≥40.0). BMI was defined as weight divided by
height (kg/m2). As previously mentioned, underweight (BMI <18.5) participants
were excluded from the study.
WC and WHR were used as measures of central adiposity. Cut-off
levels for elevated WHR matched those defined by WHO criteria (Balkau et al.,
2002), namely >0.90 for males and >0.85 for females. Elevated WC based on
sex was defined as >40 in (102 cm) waist for males and >35 in (88 cm) for
females (Swede et al., 2009).
History of a first-degree relative with CRC was defined as having a
parent, sibling, or child with a history of CRC. Personal history of polyps
was categorized as yes (a personal history of one or more polyp(s) in the past)
or no (no personal history of polyps to date).
16

Smoking status was divided into three categories: never smokers, past
smokers, and current smokers. The following groups of categories defined
alcohol consumption in analyses: red wine intake, white wine intake, beer
intake, and liquor intake. This alcohol consumption variable was further
divided into the following classification scheme: never drinkers, individuals who
consumed 0 to 3 drinks per month, and individuals who consumed ≥2 drinks
per week.
Finally, since there is a chance that people taking statins are on other
anti-inflammatory drugs, we created a composite variable that was split into
the following categories: no statin or aspirin use; statin use only; aspirin (baby
or full-dose) use only; and statin and aspirin (baby or full-dose) use to assess
the impact of individual vs. joint statin and aspirin use on ACF number.

2.5 Enzyme-Linked Immunosorbent Assays (ELISAs)

Blood specimens of 41 participants were available for ELISA analysis. The
following biomarkers from serum samples were measured: hsCRP (mg/L); IL-6
(pg/mL); TNF-a (pg/mL); Insulin (ulU/mL); Glucose; Triglyceride; Cholesterol,
Total; Cholesterol, HDL; IGF-1 (ng/mL); IGF-2 (ng/mL); IGFBP3 (ug/mL).

17

2.6 Statistical Analyses

Descriptive analyses were performed for: age, sex, BMI, WHR, WC,
medication (baby aspirin, full-dose aspirin, other NSAIDs), smoking, alcohol,
personal history of polyps, and biomarkers as correlates of statin use and in
relation to low versus high ACF number, using t-tests for continuous data and
chi-square tests for proportions.
Univariate, age-adjusted and various multivariate logistic regressions
were conducted to calculate odds ratios (ORs) and 95% confidence intervals
(95% CI) to identify the link between ACF number (i.e., outcome) and statin
use (exposure.) Statin use was assessed as regular statin use as well as the
composite variable (i.e., joint use of aspirin and statins) in models. To identify
possible confounders of the relationship between statin use and ACF number,
the univariate and age-adjusted logistic regressions were conducted for ACF
number in relation to the following variables: age, sex, BMI, WHR, WC,
medication use (baby aspirin, aspirin, other NSAIDs), smoking, alcohol
consumption, personal polyp history, family history of CRC), and biomarkers
A base multivariate model was developed to include variables that
were significant in univariate analyses (p <0.20) or were judged to be clinically
important variables. The base model included the following variables: statins,
age, sex, medication use (baby aspirin, other NSAIDs), family history of CRC
(first degree relative), personal polyp history, and smoking habits. To
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understand the effects of adiposity on ACF number, the base model was re-run
to include, separately, BMI, WHR, and WC. Also, since age is a key factor in
most disease outcomes, including CRC development and progression, all
multivariate logistic regressions were stratified by age (<50 years of age vs.
≥50 years).
Results for all tests were considered statistically significant if p<0.05 or
results within the confidence intervals (95%) did not include 1.0. SPSS version
20.0 was used, and tests were two-sided in all the analyses.
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3.0 RESULTS

3.1 Participant Characteristics

Demographics and adiposity measures of all eligible participants (n=86) are
shown in Table 1. In regards to statin use, 68.8% of the study population took
<1 pill per week and 31.3% took 1 or more pills per week. The mean age was
56.79 years (SD 8.58). Males made up 65% of the study sample while females
accounted for 35%. The majority of participants were White (90.7%), followed
by Black (8.1%) and Asian (1.2%). A slight majority (59.4%) of the participants
had some college education, a 2-year degree, or a college degree. About 21%
of the study population had completed vocational or trade school, and 17.5% of
the population had a high school education or less. Nearly 1/5 (21%) of
participants had a first degree relative (parent, sibling, or child) with a history of
CRC, and about 18% of participants had a personal history of polyps.
Regarding measures of excess body weight, the majority of participants
were overweight or obese (72.1%). Specifically, 27.9% of participants had a
normal BMI (18.5-24.9), while 41.9% were overweight (BMI of 25.0-29.9) and
30.2% were Obese (BMI of 30+). The mean waist-hip-ratio (WHR) for males
was 0.93 (SD 0.06), while the mean for females was 0.87 (SD 0.09). When
categorizing by WHO risk level, 28.6% of males had a normal WHR-risk
(≤0.90), while 57.1% of males had an elevated WHR-risk. In females, 33.3%
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had a normal WHR-risk (≤0.85), while 56.7% had an elevated WHR-risk. The
mean waist circumference for males and females, respectively, was 38.05 (SD
4.61) and 36.41 (SD 5.96). With respect to waist circumference risk, 21.2% of
males had an elevated risk (<40.0), compared to 48.1% of females (>35.0).

3.2 Correlates of Regular Statin Use

In order to identify potential confounders in the relationship between statin use
and ACF number, we explored correlates of statin use and ACF number (see
below.)

As seen in Table 2, participants who consumed at least 1 statin pill

per week (i.e., regular use of statins), had a higher mean ACF number than
participants who reported taking less than 1 pill per week (17.20 vs. 9.02,
respectively, p=0.001). We also categorized ACF number into low (<10) and
high levels (≥10). Fewer participants with low ACF number reported taking
statins on a regular basis compared to those with high ACF level (18.6%
versus 47.2, respectively, p=0.006), As expected, the mean age for patients
taking 1 or more statin pill per week was higher than the mean age for
participants on less than 1 statin pill per week (62.40 (SD 7.69) vs. 54.51 (SD
8.24), p<0.001). In addition, patients aged 50 years and older were more likely
to be on statin medication (1 or more pills per week) than those younger than
50 years old (36.8% vs. 0, p=0.014). There was no significant difference in
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percentage of males or females on statin medication (33.3% vs. 26.9%,
p=0.562).
Regarding obesity measures, the mean BMI of participants taking
statins on a regular basis was higher among those taking less than one pill per
week (30.26 (SD 5.61) vs. 27.25 (SD 4.38), p=0.011). Additionally, participants
on a regular dosage of statins were more likely to be obese than those on <1
pill per week (60.9% vs. 39.1%, p=0.001). People taking statins regularly were
also more likely to take baby aspirin on a weekly basis compared to those
taking less than 1 statin pill per week (59.3% vs. 40.7%, respectively, p=0.001).

3.3 Correlates of ACF Number

To understand the relationship between the correlates of ACF number, t-tests
for continuous data and chi-square tests for proportions were done with the
following variables: medication use (statins, baby aspirin, aspirin, other
NSAIDs), demographics (age, sex, race, education), personal polyp history,
and family history of CRC. Participants on a regular statin regimen were more
likely to have a high ACF count than participants taking <1 statin pill per week
(66.7% vs 37.1%, p=0.010). As anticipated, the mean age for participants with
a high ACF count (59.40) was higher than the mean age for participants with a
low ACF count (54.17 years, p=0.002). There were no significant differences
between low and high ACF groups for participants based on sex, race,
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education, personal polyp history, or a first degree relative with a history of
CRC (Table 4).
Adiposity was explored as a correlate of ACF number (high vs. low) by
analyzing BMI, WHR, WHR-risk, and WC. As predicted, the mean BMI for the
low ACF group was less than that of the high ACF group (27.21 vs. 28.99,
respectively, p=0.152). There were no significant differences between the low
and high ACF groups in waist-hip-ratio, waist-hip ratio risk level, or waist
circumference. There was a marked difference, however, when smoking was
analyzed as a correlate of ACF (Table 6). Never and past smokers were more
likely to be in the low ACF group than current smokers (58.9% vs. 60.0% vs.
18.2%, p=0.037). Eighty-one percent of current smokers fell into the high ACF
group vs. 40.0% and 41.1% of past and never smokers, respectively. There
were no significant differences between beer, red wine, and white wine
consumption and ACF count. Almost 82% of participants that consumed 2 or
more drinks of liquor per week, however, had high ACF, compared to 42.9 and
40.4% of participants who had 0-3 drinks per month or did not drink on a
regular basis (p=0.039). When serum biomarkers were analyzed as correlates
of ACF, there were no significant differences between the measured
biomarkers and ACF count, with the exception of insulin levels (Table 7). The
mean level of insulin (ulU/mL) in the high ACF group compared to the low ACF
group was 5.84 vs. 3.44 (p=0.035).
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3.4 Univariate and Age-Adjusted Logistic Regression Assessing the
Relationship between Regular Statin Use and ACF Number

We calculated univariate and age-adjusted Odds Ratios (ORs) and 95%
Confidence Intervals (95% CIs) in order to identify variables that might have an
association between statin use and ACF number (Table 8). Compared to
people taking <1 statin pill per week, people with regular statin use were 3.91
times more likely to have a high ACF count (95%CI=1.43-10.74, p=0.008).
Age, current smoking, and frequent liquor intake were also shown to increase
the risk for having a high ACF count. Participants age 50 years and older were
3 times more likely to have high ACF than those younger than age 50
(95%CI=0.77-12.32), and current smokers had a 4.90 times greater odds of
having high ACF compared to never smokers (95%CI=0.92-26.11).
Additionally, the age-adjusted OR for high ACF was 6.21 (95%CI= 1.22-31.78)
when comparing users of high level of liquor (≥3 drinks per week) with never
users of liquor. No significant differences in the logistic regression were noted
for the following variables: sex, BMI, WHR, WC, baby aspirin, aspirin, other
NSAIDs, red white, white wine, beer, personal history of polyps, and family
history of CRC.
Age-adjusted ORs for the logistic regression are shown in Table 8. After
adjusting for age, the OR for high ACF of taking ≥1 statin pill per week vs.
taking <1 pill per week decreased to 2.67 (95%CI=0.89-7.97) and was no long
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statistically significant. The OR for high ACF and being a current smoker
compared to being a non-smoker, on the other hand, increased to 7.17
(95%CI=1.22-42.17) and became statically significant (p=0.029). The OR for
high ACF of having a high intake of liquor vs. no liquor intake increased to 7.13
(95%CI=1.33-38.35) and remained statistically significant (p=0.022) after age
adjustment.
Univariate and age-adjusted ORs and 95% CIs were additionally
measured in order to identify serum inflammatory or adiposity-related
biomarkers that might have an association between statin use and ACF
number (Table 9). Insulin was the only biomarker that showed statistical
significance in the crude and age adjusted logistic regressions (Crude OR: 1.31
(95%CI=1.01-1.70), p=0.045; Age-adjusted OR: 1.33 (95%CI=1.01-1.75)
p=0.039). The following serum biomarkers were not significantly associated
with ACF number in both the crude- and age-adjusted logistic regressions:
IGF-2, hsCRP, IGFBP3, IGF1, IL-6, TNF-a, glucose, total cholesterol, and HDL
cholesterol.

3.5 Base Multivariate Logistic Regression

Variables that were related to ACF in the Univariate model or were judged to
have clinical value were placed in the multivariate model. The results for the
multivariate regression base model can be found in Table 10. The OR for high
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ACF in relation to regular statin use compared to no statin use was 1.47
(95%CI=0.28-7.74). Unlike the univariate estimate, this was no longer
statistically significant (p=0.652). The OR for high ACF of age was 1.10
(95%CI=0.99-1.22; p=0.065), and the OR for high ACF of being a current
smoker in comparison to having never smoked was 4.80 (95%CI=0.61-37.68;
p=0.136) in the multivariate logistic regression. There was no statistical
significance of any variables after stratifying the base model by age (≥50 years
vs. <50 years old) (Table 14).

3.6 Adding Obesity Measures into the Base Multivariate Model

In order to understand if adiposity influences the association between ACF
number and statin use, BMI, WHR, and WC were added into the base model
individually. The results for the multivariate logistic regression BMI model can
be found in Table 11. The OR for high ACF of regular statin use compared to
no statin use was 1.24 (95%CI=0.21-7.47; p=0.017). The OR for high ACF of
age was 1.11 (95%CI=1.00-1.23; p=0.063). Current smokers had more than 5
times greater odds of having high ACF than non-smokers (OR: 5.43;
95%CI=0.64-46.32; p-0.122). After stratifying for age (≥50 years vs. <50 years
old), there was no longer statistical significance of any of the variables
measured in the BMI model.
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The results for the multivariate logistic regression WHR model can be
found in Table 12. The OR for high ACF and regular statin use compared to no
regular statin intake was 0.68 and no longer statistically significant
(95%CI=0.10-5.40; p=0.702). Age, however, was significantly associated with
high ACF number in the WHR model. The OR for age was 1.15 (95%CI=1.011.32; p=0.035), and the OR for high ACF of being a current smoker compared
to non-smokers was 7.62 (95%CI=0.79-73.37; p=0.079). After stratifying for
age (≥50 years vs. <50 years old) (Table 16), none of the variables showed
statistical significance any longer.
The results for the multivariate logistic regression WC model can be
found in Table 13. The OR for high ACF of regular statin use vs. no statin use
was 1.20 (95%CI=0.20-1.20; p=0.842). The OR for high ACF of age was 1.12
(95%CI=0.99-1.26; p=0.62) and the OR for high ACF of being a current smoker
vs. non-smoker was 2.58 (95%CI=0.54-38.54; p=0.162). After age
stratification (≥50 years vs. <50 years old) (Table 17), there was still no
statistical significance for statin use. The OR for high ACF of age was 1.19
(95%CI=1.00-1.41; p=0.054), and the OR for high ACF of currently smoking vs.
non-smoking was 3.30 (95%CI=0.25-43.07; p=0.363). No variables showed
statistical significant in either of the WC models.
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3.7 Composite Variable of Joint Aspirin and Statin Use

In assessing the impact of joint statin and aspirin use, compared to individual
use of these medications, we found that the crude OR for high ACF of taking
statins compared to no statins or aspirin was 15 (p=0.019), compared to 1.83
(p=0.293) for aspirin only, and 4.29 (0.022) for statins and aspirin. After
adjusting for age, they reduced to 11.03 (p=0.042), 1.35 (p=0.622), and 2.26
(p=0.265), respectively. After controlling for age, sex, NSAID use, family
history of CRC, personal polyp history, and smoking in the multivariate model,
the OR for high ACF of taking statins compared to no statin or aspirin use was
2.06 (p=0.620), compared to 0.45 (p=0.369) for aspirins only, and 0.45
(p=0.535) for statins and aspirins. Results for the composite statin and aspirin
variable can be found in Table 17.
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4.0 DISCUSSION

4.1 Key Findings

About 30% of our study population took statins on a regular basis (i.e., ≥1 pill
per week for the past 12 months). Participants on a regular statin regimen had
almost twice the number of mean ACF than those not taking statins regularly,
which was statistically significant. Additionally, two-thirds of participants with
regular statin use were categorized as having high ACF in comparison to a little
over a third of participants who reported little or no statin use. Univariate
logistic regression analyses showed that patients regularly taking statins had
close to four times the likelihood of high levels of ACF than those not taking
statins regularly. After adjustment for age, the OR reduced to just below 3.0
but did not remain statistically significant. When potential confounders were
placed in the multivariate base model, this effect lessened, more so, with statin
users having an approximately 1.5 times greater odds of having high ACF than
non-statin users. OR estimates from neither the base model nor each of the
three models with the adiposity measures were statically significant.
When examining joint use of statins and aspirin, univariate logistic
regression suggested that participants who consumed statins (only) on a
regular basis were 15 times more likely to have a high ACF count compared to
the reference group of participants who consumed neither aspirin nor statins
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regularly. In the age-adjusted and multivariate models, however, this effect
was attenuated substantially and became non-significant. Of note, though not
statistically significant, the odds of having a high ACF count among statin-only
users was 2 times greater than odds among users of neither statin nor aspirin.

4.2 Consistency with Prior Studies on Statins and Colorectal Neoplasia

Our univariate logistic regression analyses of a positive association with ACF
number are inconsistent with animal studies, which have suggested uniformly
that statins lower the risk of colonic neoplasia (NCI, 2005). As predicted,
virtually all of our multivariate analyses reduced the OR estimates to null. One
such animal study, Narisawa et al. (1994), examined the effects of pravastatin
and simvastatin on mice that received injections of 1,2-dimethylhydrazine
(DMH) to induce colon cancer development and found that the incidence of
colon tumors examined at weeks 25 or 30 was reduced by 67% in the
pravastatin group and by 30% in the simvastatin group (Narisawa et al., 1994).
While these results did not reach statistical significance, there was a
considerable reduction in the number of tumors per mouse in both groups
(Narisawa et al., 1994).
Evidence from human studies has been quite mixed. We believe, in
part, this is due to all reports on statins and colonic neoplasia in humans
having been derived from secondary analyses, with the recent exception of a
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multicenter, phase II trial of statins for CRC chemoprevention by Limburg et al.
(2011). Using ACF as the intermediate endpoint, Limburg (2011) reported a
lack of convincing evidence that six months of statin use (atorvastatin or
sulindac) reduced ACF number.
Singh et al. (2009) did not find any statistically significant reductions in
CRC risk with regular use of statins, irrespective of duration and dose. Oddly,
however, they did find a slightly increased risk with low dose statin intake
among regular users compared to nonusers of statins. Low doses of statins
have been shown to have a stimulatory effect on CRC cell lines (Kodach et al.,
2007). Poynter et al. (2005) reported a 47% reduction in CRC risk among
individuals using statins for 5 or more years. Hence, ascertaining dose may be
in critical in human studies.
A recent study by Bertagnolli et al. (2010) suggests that for patients at
high risk of CRC (e.g., patients with multiple adenomas or patients who have
had a single adenoma ≥6 mm in diameter removed), statins do not protect
against colorectal neoplasms and may even increase the risk of developing
adenomas. These findings are consistent with early clinical trials that suggest
that statin use might increase cancer risk (Alsheikh & Karas, 2009; Oliver,
1991; Rossebo et al., 2008; Shepherd et al., 2002). In the Bertagnolli (2010)
study, participants who used statins for more than 3 years in the placebo group
of the Adenoma Prevention with Celecoxib (APC) trial showed a 40% increase
in adenoma detection over 5 years of surveillance.
31

On the other hand, Siddiqui et al. (2009) found that long-term statin use
was associated with a 29% reduction in the incidence of new and advanced
adenomatous colon polyps (APs) in patients that had previously had APs
removed colonoscopically. This association remained, even after controlling
for other known risk factors (Siddiqui et al., 2009). These data suggest that
statins may decrease the development of CRC by reducing the development of
new APs (Siddiqui et al., 2009), yet it is unknown what the incidence of ACF
was.
Regarding evidence of indication bias related to adiposity, our study is
inconclusive in that OR estimates were reduced in the base model prior to the
introduction of adiposity measures into the model. While our adiposity results
are not statistically significant, our data do show similar tends to Swede et al.
(2009) in that higher adiposity levels seem to be associated with high ACF
count.

In terms of the association between adiposity and ACF number,

Swede et al. (2009) found that high ACF count was significantly associated
with higher BMI, WHR, and WC compared to people with low ACF. However,
high ACF was defined as ≥5 whereas the cut point for the current study count
was 10 ACF.
Our descriptive findings on the relationship between elevated BMI,
WHR, and WC and increased ACF number are also consistent with a report by
Takahashi et al. (2007), who found that a high level of visceral fat was
associated with elevated ACF number. While our findings do not show a
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statistically significant relationship between high ACF number and obesity, high
WHR, and high WC, we did observe similar general trends. Individuals who
were obese (BMI ≥30) were more likely to have a higher ACF count than
individuals with normal BMI (18.5-24.9). Additionally, both males and females
with high ACF had slightly higher mean WHR values. Our findings are
consistent with findings reported by Swede et al. (2009), in terms of this
relationship being stronger in females than males. Furthermore, over half of
participants with elevated WHR-risk were more likely to fall into the high ACF
group.
In relation to WC, both males and females in the high ACF group tended
to have a higher mean WC. Females in the high ACF group had a slightly
higher mean WC than that of those in the low ACF group. In males, this
association was slightly stronger. While our findings reported WC to be
associated with high ACF more strongly in males, Swede et al. (2009) found
the opposite. Females with a higher WC were more strongly associated with
high ACF than males (p=0.06 for females; p=0.17 for males) (Swede et al.,
2009).
In reference to other lifestyle behaviors that affect CRC risk, smoking
use and alcohol consumption are thought to induce ACF (Lopez-Ceron &
Pellise, 2011). However, the effects of different types of alcoholic beverages
(e.g. beer, liquor, wine) are not well understood (Lopez-Ceron & Pellise, 2011).
In our study, over 80% of current smokers had high ACF. Current smokers
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had an almost 5 times greater odds of having high ACF as opposed to nonsmokers in the multivariate model. Additionally, frequent liquor consumption
was significantly associated with high ACF count.
In regards to family history of CRC, Stevens et al. (2007) reported a
significantly higher mean ACF number in patients with a positive family history
of CRC in a first degree relative or a personal history of CRC (p<0.01 and
p<0.05, respectively). Surprisingly, having a first-degree relative with CRC did
not make participants more likely to have a higher ACF number in our study,
nor did we see a link with polyps.
In terms of conventional anti-inflammatory medications, many
observational studies have noted a lower CRC risk in association with regular
intake of aspirin or NSAIDs (Simon, 2012). This was not quite as clear in our
study, but, as described below, our findings about ACF were consistent with
other observational studies in that there was a lower percentage of participants
with high ACF in regular users of these anti-inflammatory medications in
comparison to non-regular users.
Regarding baby aspirin use, we found that about two-thirds of
participants taking low levels (i.e., <1 pill per week for past 12 months) had
high ACF, compared to about half of regular aspirin users. Among regular
aspirin users, 30% had a high ACF count compared to almost 62% of
participants who took <1 pill per week.
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While many studies have found that the sustained use of aspirin and
other NSAIDs may decrease the incidence of APs and CRC and may decrease
the mortality rate from CRC (Siddiqui et al., 2009), the gastrointestinal and
other serious toxicities of NSAIDs limit their utility for the chemoprevention of
CRC, especially in the older populations in which CRC is most prevalent
(Siddiqui et al., 2009).
Age was significantly associated with high ACF count in our study.
Participants on regular statins had a mean age 5 years greater than those
taking <1 pill per week. People older than 50 that took statins did have slightly
increased odds of high ACF in comparison to those younger than 50 in the
multivariate model. Swede et al. (2009), however, did not find age to be
significantly associated with high ACF. The mean age of individuals in the high
ACF group (≥5 ACF) was slightly higher than the low ACF group (<5 ACF).

4.3 Strengths and Limitations

A major advantage of our study was the creation of a composite variable in
which we assessed joint statin and aspirin use. Since, it is likely that patients
on statins could be on other anti-inflammatory drugs (i.e., aspirin) for the longterm, we were able to examine the effects of statin use alone. Our results
should be approached with caution, however, as we had a very small sample
size in one of our study groups (e.g., n=7 for statins only). Understanding the
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impact of a combination of different medications, and taking into account
confounding between medications, should be a goal of future studies. Another
strength of our study was that several inflammatory, adiposity, and lipidassociated biomarkers were assessed in relation to ACF number. Perhaps
because of the small number of patients with these values (n=41), results were
not conclusive. Also, the link between alcohol use and colonic neoplasia is not
well understood, but we were able to broadly examine it in this study by
comparing beer, liquor and wine intake to ACF count.
There are several limitations of this study. First, dietary intake and
physical activity were not taken into account in our multivariate model. Both of
these have shown to have an impact on ACF number and CRC risk and could
have affected our results. Due to several methodical issues in measuring and
evaluating physical activity, we chose not to include it in our study. A second
limitation of this study is that biomarker levels were measured as one point in
time. It is conceivable that serum levels of some biomarkers (cholesterol,
insulin, glucose, etc.) can vary from baseline to reassessment. ACF number
also shows dynamic variability (Schoen et al., 2008), but was measured at only
a single point in time
Another key limitation of this study is the small size of the study
population. The number of people taking ≥1 statin pill per week (i.e., regular
statin use) was very low (n=25, 31.3%). This could potentially have resulted in
unreliable estimates. Finally, type of statin use may influence tissue response
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(Bertagnolli et al., 2010). While hydrophilic statins (e.g., fluvastin, rosuvastatin,
pravastatin) are hepatoselective, lipophilic statins (e.g., lovastatin, simvastatin,
atorvastin) tend to achieve higher drug levels in nonhepatic tissues and are
thought to alter colorectal mucosa more (Bertagnolli et al., 2010). In an
analysis using the Women’s Health Initiative, Simon et al. (2012) found no
overall protective effect of statins for CRC. A significant reduction was
observed in CRC risk, however, for lovastatin users and a modest, but
insignificant reduction for overall statin use of ≥3 years.

4.4 Conclusions

While statin use was associated with a significantly higher ACF count in our
study population in univariate analyses, this effect did not remain after
controlling for confounders. After adding measures of adiposity (BMI, WHR,
WC) to the multivariate base model, only increased age and current smoking
status remained associated with ACF number. Since CRC can take up to 20
years to develop, insufficient drug exposure and follow-up could be the culprit
to a lack of consensus on the topic (Bertagnolli et al., 2010).
Future studies should focus more on length of time of statin use,
perhaps by breaking it down into more discrete categories, as well as type of
statin and dosage. Additionally, regular use of statins needs to be
standardized. Most studies define regular statin use differently, making it
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difficult to compare results. Finally, there is a need for studies to address
indication bias, especially as adiposity continues to garner interest as a
modifiable risk factor in CRC. It could be that statins are prescribed more often
to people who are at high risk of acquiring CRC. Thus, it could appear that
statins are causing high ACF number, when they are in fact being prescribed
more often to those at high risk for CRC. Further exploration of these topics
may provide a greater understanding of the inter-relationships of statins,
adiposity, and CRC, leading to effective preventive interventions that will
improve the public health.
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Table 1: Description of Study Population (n=86)

Statin Use in Past 12 months
Age (mean, SD)
Age
Sex
Race

Education

<1 pill per week
≥1 pill per week
<50 yrs
≥50 yrs
Male
Female
White
Black
Asian
Less than High School
High School or GED
Vocational or Trade School
Some College
2-year Degree
At Least College Degree

1st Degree Relative with CRC

Yes
No
Yes
No

Personal History of Polyps
BMI

Waist-hip-ratio (mean, SD)
Waist-Hip-Ratio Risk

Waist Circumference (mean, SD)
Waist Circumference Risk

Normal (18.5-24.9)
Overweight (25.0-29.9)
Obese (30+)
Male
Female
Male
Normal (≤0.90)
High (>0.90)
Female
Normal (≤0.85)
High (>0.85)
Male
Female
Male

Normal (≤40.0)
High (>40.0)
Normal (≤35.0)
High (>35.0)

Female
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55 (68.8%)
25 (31.3%)
56.79 (8.58)
12 (14%)
74 (86%)
56 (65.1%)
30 (34.9%)
78 (90.7%)
7 (8.1%)
1 (1.2%)
5 (5.9%)
10(11.6%)
18 (20.9%)
20 (23.3%)
17 (19.8%)
14 (16.3%)
18 (20.9%)
61 (70.9%)
14 (17.7%)
65 (82.3%)
24 (27.9%)
36 (41.9%)
26 (30.2%)
0.93 (0.06)
0.87 (0.09)
16 (28.6%)
32 (57.1%)
10 (33.3%)
17 (56.7%)
38.05 (4.61)
36.41 (5.96)
41 (78.8%)
11 (21.2%)
14 (51.9%)
13 (48.1%)

Table 2: Correlates of Regular Statin Use (n=86)
Weekly Statin Use
Past 12 Months
<1 pill
≥1 pill
ACF number
9.02
17.20
ACF Number
Low (<10)
35 (81.4%)
8 (18.6%)
High (≥10)
19 (52.8%)
17 (47.2%)
Age (mean, SD)
54.51 (8.24)
62.40 (7.69)
Age
<50 years
12 (100%)
0
≥ 50 years
43 (63.2%)
25 (36.8%)
Sex
Male
36 (66.7%)
18 (33.3%)
Female
19 (73.1%)
7 (26.9%)
1st Degree Relative with CRC
Yes
12 (66.7%)
6 (33.3%)
No
38 (69.1%)
17 (30.9%)
Personal History of Polyps
Yes
13 (65.0%)
7 (35.0%)
No
30 (75.0%)
10 (25.0%)
Body Mass Index (mean, SD)
27.25 (4.38)
30.26 (5.61)
Body Mass Index
Normal [18.5-24.9]
18 (75.0%)
6 (25.0%)
Overweight [25.0-29.9]
28 (84.8%)
5 (15.2%)
Obese [30+]
9 (39.1%)
14 (60.9%)
Sex-specific Waist-Hip-Ratio Risk Normal
21 (80.8%)
5 (19.2%)
Elevated
27 (61.4%)
17 (38.6%)
Waist Circumference (mean, SD)
36.44 (4.87)
39.28 (5.10)
Baby Aspirin
Never
41 (82.0%)
9 (18.0%)
<1 pill/week
2 (100%)
0
≥1 pill/week
11 (40.7%)
16 (59.3%)
Regular Aspirin
Never
39 (68.4%)
18 (31.6%)
<1 pill/week
10 (76.9%)
3 (23.1%)
≥1 pill/week
6 (60.0%)
4 (40.0%)
Other NSAIDS
Never
24 (77.4%)
7 (22.6%)
<1 pill/week
20 (74.1%)
7 (25.9%)
≥1 pill/week
11 (50.0%)
11 (50.0%)
Smoking
Never
34 (70.8%)
14 (29.2%)
Past
16 (66.7%)
8 (33.3%)
Current
5 (62.5%)
3 (37.5%)
Alcohol
Red Wine Never
32 (71.1%)
13 (28.9%)
0-3 drinks /month
12 (63.2%)
7 (36.8%)
≥2 drinks per week
10 (66.7%)
5 (33.3%)
White Wine Never
39 (67.2%)
19 (32.8%)
0-3 drinks /month
5 (71.4%)
2 (28.6%)
≥2 drinks per week
10 (71.4%)
4 (28.6%)
Beer Never
28 (62.2%)
17 (37.8%)
0-3 drinks /month
13 (68.4%)
6 (31.6%)
≥2 drinks per week
13 (86.7%)
2 (13.3%)
Liquor Never
36(72.0%)
14 (28.0%)
0-3 drinks /month
12 (66.7%)
6 (33.3%)
≥2 drinks per week
6 (54.5%)
5 (45.5%)
1
T-tests for independent samples for continuous data and chi-square test for proportions
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p-value1
0.001
0.006
<0.001
0.014
0.562
0.969
0.418
0.011
0.001

0.091
0.022
0.001

0.683

0.080

0.865

0.813
0.939
0.211
0.522

Table 3: Correlates of Statin Use: Biomarkers Related to Inflammation, Insulin Resistance, and Lipid Levels
(n=41)

hsCRP, mg/L
IL-6, pg/mL
TNF-a, pg/mL
Insulin, ulU/mL
Glucose
Triglyceride
Cholesterol, Total
Cholesterol, HDL
IGF-1, ng/mL
IGF-2, ng/mL
IGFBP3, ug/mL

Never
4.22
62.86
5.78
4.41
88.17
105.83
185.72
49.94
122.80
758.16
5.07

Weekly Statin Use
Past 12 Months
≥1 pill
p-value1
4.94
0.734
31.10
0.282
4.17
0.234
4.38
0.980
89.29
0.913
88.07
0.245
189.86
0.705
58.43
0.166
110.64
0.235
685.07
0.064
4.44
0.045
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Table 4: Correlates of ACF Number: Demographics, Medication Use, Personal Polyp History, and 1st Degree
relative with Colorectal Cancer (n=86)
ACF Number
Low (<10)
High (≥10)
Statin Use
<1 pill/week
39 (62.9%)
23 (37.1%)
(Past 12 months)
≥1 pill/week
9 (33.3%)
18 (66.7%)
Baby Aspirin
None
30 (60.0%)
20 (40%)
<1 pill/week
1 (33.3%)
2 (66.7%)
≥1 pill/week
12 (46.2%)
14 (53.8%)
Aspirin
None
31 (54.4%)
26 (45.6%)
<1 pill/week
5 (38.5%)
(8) 61.5%
≥1 pill/week
7 (70.0%)
3 (30.0%)
Other NSAIDs
None
19 (61.3%)
12 (38.7%)
<1 pill/week
13 (48.1%)
51.9% (14)
≥1 pill/week
11 (50%)
11 (50%)
Age (years)
Mean
54.17
59.40
Range
51.82-56.52
57.03-61.78
Sex
Male
33 (52%)
29 (46.8%)
Female
19 (57.6%)
14 (42.4%)
Race
White
42 (54.5%)
35 (45.5%)
Black
2 (28.6%)
5 (71.4%)
Asian
1 (100%)
0
Education
Less than High School
1 (20%)
4 (80%)
High School or GED
6 (60%)
4 (40%)
Vocational/Trade School
12 (66.7%)
6 (33.3%)
Some College
9 (45%)
11 (55%)
2 Year Degree
8 (50%)
8 (50%)
4 or 5 Year Degree
9 (64.3%)
5 (35.7%)
Personal Polyp History
Yes
9 (42.9%)
12 (57.1%)
No
24 (61.5%)
15 (38.5%)
1st Degree Relative with Yes
11 (61.1%)
7 (38.9%)
CRC
No
31 (51.7%)
29 (48.8%)
1
T-tests for independent samples for continuous data and chi-square test for proportions
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p-value1
0.010
0.390

0.381

0.556

0.002
0.685
0.268

0.520

0.165
0.668

Table 5: Correlates of ACF Number: Adiposity

ACF Number
Low (<10)
High (≥10)
Body Mass Index (kg/m2)
27.21 (SD)2
28.99 (SD)
Body Mass Index
Normal [18.5-24.9]
14 (58.3%)
10 (41.7%)
Overweight [25.0-29.9]
20 (57.1%)
15 (42.9%)
Obese [≥30]
11 (42.3%)
15 (57.5%)
Waist-Hip-Ratio
Male
0.92 (0.07)
0.93 (0.06)
Female
0.86 (0.07)
0.89 (0.11)
Waist-Hip-Ratio Risk
Normal
18 (62.1%)
11 (37.9%)
Elevated
24 (47.1%)
27 (52.9%)
Waist Circumference
Male
37.14 (5.23)
38.89 (3.87)
Female
36.22 (5.85)
36.59 (6.59)
1
T-tests for independent samples for continuous data and chi-square test for proportions
2

Mean (SD)
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p-value1
0.152
0.634

0.788
0.405
0.196
0.174
0.883

Table 6: Correlates of ACF Number: Smoking and Alcohol

ACF Number
Low (<10)
High (≥10)
Smoking Never
33 (58.9%)
23 (41.1%)
Past
15 (60.0%)
10 (40.0%)
Current
2 (18.2%)
9 (81.8%)
Alcohol
Beer
Never 27 (50.9%)
26 (49.1%)
0-3 drinks/month 13 (61.9%)
8 (38.1%)
≥2 drinks/week 8 (53.3%)
7 (46.7%)
Liquor
Never 34 (59.6%)
23 (40.4%)
0-3 drinks/month 12 (57.1%)
9 (42.9%)
≥2 drinks/week 2 (18.2%)
9 (81.8%)
Red Wine
Never 28 (53.8%)
24 (46.2%)
0-3 drinks/month 10 (47.6%)
11 (52.4%)
≥2 drinks/week 10 (62.5%)
6 (37.5%)
White Wine
Never 37 (56.1%)
29 (43.9%)
0-3 drinks/month 4 (50.0%)
4 (50.0%)
≥2 drinks/week 7 (46.7%)
8 (53.3%)
1
T-tests for independent samples for continuous data and chi-square test for proportions

51

p-value1
0.037

0.694
0.039
0.667
0.783

Table 7: Correlates of ACF Number: Biomarkers of Inflammation, Insulin Resistance, and Lipid Levels (n=41)

ACF Number
Low (<10)
High (≥10)
hsCRP (mg/L)
4.09 (4.08)1
5.39 (7.23)1
IL-6 (pg/mL)
87.79 (215.97)
57.90 (99.82)
TNF-a (pg/mL)
5.45 (3.66)
4.51 (3.24)
Insulin (ulU/mL)
3.44 (2.78)
5.84 (3.16)
Glucose
86.72 (27.93)
90.47 (28.20)
Triglyceride
97.33 (48.20)
98.47 (33.87)
Cholesterol, Total
185.78 (28.02)
186.33 (34.72)
Cholesterol, HDL
52.00 (12.09)
54.27 (22.16)
IGF-1 (ng/mL)
116.54 (21.38)
126.07 (37.05)
IGF-2 (ng/mL)
710.96 (110.43)
772.05 (116.38)
IGFBP3 (ug/mL)
4.80 (0.95)
5.05 (1.04)
1
Standard deviation for continuous variables
2
T-tests for independent samples for continuous data
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p-value2
0.507
0.614
0.473
0.035
0.705
0.939
0.960
0.712
0.348
0.121
0.457

Table 8: Univariate and Age-Adjusted Odds Ratios and 95% Confidence Intervals for ACF Number in relation to
Key CRC Risk Factors
Crude
OR (95% CI)
Statins
Age
Age
Sex
BMI
BMI

<1 pill per week
≥ 1 pill per week
< 50 years
≥ 50 years

Normal
Overweight
Obese
Normal
Elevated

Sex-specific WaistHip-Ratio Risk
Waist Circumference
Baby Aspirin
Aspirin
Other NSAIDs
<1 pill per week
≥ 1 pill per week
Smoking
Never
Past
Current
Red Wine
None
0-3 drinks per month
≥ 3 drinks per week
White Wine
None
0-3 drinks per month
≥ 3 drinks/week
Beer
None
0-3 drinks per month
≥ 3 drinks per week
Liquor
None
0-3 drinks per month
≥ 3 drinks per week
Personal Polyp
Yes
History
No
1st Degree Relative
Yes
with CRC
No

1.00
3.91 (1.43-10.74)
1.08 (1.02-1.14)
1.00
3.08 (0.77-12.32)
0.71 (0.29-1.75)
1.06 (0.98-1.16)
1.00
0.95 (0.33-2.73)
1.82 (0.65-5.08)
1.00
1.89 (0.72-5.00)
1.06 (0.96-1.15)
1.64 (0.64-4.23)
0.45 (0.11-1.90)
1.00
1.23 (0.46-3.29)
1.00
1.00 (0.37-2.70)
4.90 (0.92-26.11)
1.00
1.27 (0.43-3.72)
0.76 (0.23-2.50)
1.00
1.76 (0.36-8.58)
1.76 (0.54-5.72)
1.00
0.76 (0.26-2.24)
0.92 (0.28-2.95)
1.00
0.88 (0.29-2.64)
6.21 (1.22-31.78)
1.00
0.47 (0.16-1.38)
1.00
1.89 (0.62-5.77)
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Age-Adjusted
p-value

OR (95% CI)

p-value

0.818
0.028

1.00
2.67 (0.89-7.97)
1.00
1.10 (0.21-1.15)
0.65 (0.25-1.71)
1.06 (0.97-1.14)
1.00
0.95 (0.31-2.91)
1.68 (0.58-4.81)
1.00
1.50 (0.53-4.21)
1.04 (0.95-1.14)
0.89 (0.30-2.66)
0.44 (0.10-1.91)
1.00
1.15 (0.42-3.19)
1.00
1.02 (0.35-2.97)
7.17 (1.22-42.17)
1.00
1.23 (0.40-3.85)
0.69 (0.20-1.14)
1.00
1.67 (0.32-8.64)
1.67 (0.49-5.76)
1.00
0.93 (0.29-2.92)
1.32 (0.38-4.61)
1.00
0.90 (0.28-2.89)
7.13 (1.33-38.35)

0.169

0.64 (0.20-2.02)

0.446

0.261

1.78 (0.55-5.88)

0.337

0.008
0.009
0.111
0.451
0.159
0.928
0.254
0.199
0.243
0.303
0.279
0.679
1.000
0.063
0.663
0.654
0.484
0.347
0.620
0.881

0.079
0.910
0.385
0.207
0.927
0.337
0.443
0.431
0.833
0.272
0.784
0.969
0.029
0.719
0.554
0.540
0.414
0.897
0.663
0.855
0.022

Table 9: Univariate and Age-Adjusted Odds Ratios and 95% Confidence Intervals for ACF Number in relation to
Biomarkers of Inflammation, Insulin Resistance and Lipid Levels
Crude

IGF-2
hsCRP
IGFBP3
IFG1
Insulin
IL-6
TNF-a
Glucose
Triglyceride
Cholesterol, total
Cholesterol, HDL

Age Adjusted

OR (95% CI)

p-value

OR (95% CI)

p-value

1.01 (0.10-1.01)
1.03 (0.91-1.16)
1.40 (0.62-3.14)
1.01 (0.99-1.04)
1.31 (1.01-1.70)
1.03 (0.99-1.01)
0.92 (0.73-1.16)
1.01 (0.98-1.03)
1.00 (0.98-1.02)
1.00 (0.98-1.02)
1.01 (0.97-1.05)

0.112
0.686
0.421
0.362
0.045
0.561
0.463
0.696
0.937
0.958
0.702

1.01 (1.00-1.01)
1.04 (.91-1.18)
1.46 (.62-3.42)
1.02 (.99-1.05)
1.33 (1.01-1.75)
1.00 (1.00-1.01)
0.93 (0.73-1.18)
1.01 (0.98-1.04)
1.00 (0.99-1.02)
1.00 (0.98-1.02)
1.00 (0.96-1.04)

0.117
0.605
0.388
0.201
0.039
0.418
0.547
0.530
0.863
0.926
0.950
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Table 10: Multivariate ORs and 95% CIs in relation to ACF Number- Base Model
Adjusted OR
Statins
Age
Sex
Baby Aspirin
All Other NSAIDs
1st Degree Relative with CRC
Personal History of Polyps
Smoking

<1 pill per week
≥ 1 pill per week

1.00
1.47
1.10
1.00
0.96
1.00
0.79
1.00
0.67
1.00
1.25
1.00
1.08
1.00
0.76
4.80

Male
Female
<1 pill per week
≥ 1 pill per week
<1 pill per week
≥ 1 pill per week
Yes
No
Yes
No
Never
Past
Current
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95% CI

p-value

0.28-7.74
0.99-1.22

0.652
0.065

0.26-3.51

0.952

0.17-3.64

0.762

0.15-3.05

0.608

0.26-6.00

0.783

0.26-4.43

0.915

0.19-3.05
0.61-37.68

0.704
0.136

Table 11: Multivariate ORs and 95% CIs in relation to ACF Number: - BMI added to Base Model
Adjusted OR
Statins
Age
Sex
Baby Aspirin
All Other NSAIDs
1st Degree Relative with CRC
Personal History of Polyps
Smoking

<1 pill per week
≥ 1 pill per week

1.00
1.24
1.11
1.00
1.03
1.00
0.73
1.00
0.69
1.00
1.15
1.00
1.11
1.00
0.85
5.43
1.04

Male
Female
<1 pill per week
≥ 1 pill per week
<1 pill per week
≥ 1 pill per week
Yes
No
Yes
No
Never
Past
Current

BMI

56

95% CI

p-value

0.21-7.47
1.00-1.23

0.817
0.063

0.27-3.89

0.967

0.15-3.55

0.694

0.15-3.14

0.627

0.24-5.62

0.862

0.27-4.60

0.890

0.20-3.54
0.64-46.32
0.89-1.22

0.817
0.122
0.637

Table 12: Multivariate ORs and 95% CIs in relation to ACF Number: WHR added to Base Model
Adjusted OR
Statins
Age
Sex
Baby Aspirin
All Other NSAIDs
1st Degree Relative with CRC
Personal History of Polyps
Smoking

<1 pill per week
≥ 1 pill per week

1.00
0.68
1.15
1.00
1.03
1.00
0.98
1.00
0.93
1.00
1.10
1.00
1.30
1.00
0.66
7.62
0.03

Male
Female
<1 pill per week
≥ 1 pill per week
<1 pill per week
≥ 1 pill per week
Yes
No
Yes
No
Never
Past
Current

Waist-Hip-Ratio
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95% CI

p-value

0.10-5.40
1.01-1.32

0.702
0.035

0.24-4.43

0.969

0.18-5.40

0.984

0.19-4.58

0.931

0.21-5.63

0.914

0.25-6.80

0.754

0.11-3.92
0.79-73.37
0.00-412.07

0.648
0.079
0.473

Table 13: Multivariate ORs and 95% CIs in relation to ACF Number: WC added to Base Model
Adjusted OR
Statins
Age
Sex
Baby Aspirin
All Other NSAIDs
1st Degree Relative with CRC
Personal History of Polyps
Smoking

<1 pill per week
≥ 1 pill per week

1.00
1.20
1.12
1.00
0.91
1.00
0.62
1.00
0.61
1.00
1.24
1.00
0.95
1.00
1.00
2.58
1.02

Male
Female
<1 pill per week
≥ 1 pill per week
<1 pill per week
≥ 1 pill per week
Yes
No
Yes
No
Never
Past
Current

Waist Circumference

58

95% CI

p-value

0.20-7.36
0.99-1.26

0.842
0.062

0.23-3.59

0.893

0.17-3.26

0.569

0.13-2.89

0.536

0.25-6.22

0.793

0.20-4.55

0.949

0.19-5.17
0.54-38.54
0.88-1.17

0.999
0.162
0.829

Table 14: Multivariate ORs and 95% CIs in relation to ACF Number: Age-stratified (≥50 yrs) Base Model
Adjusted OR
Statins
Age
Sex
Baby Aspirin
All Other NSAIDs
1st Degree Relative with CRC
Personal History of Polyps
Smoking

<1 pill per week
≥ 1 pill per week

1.00
1.48
1.09
1.00
1.04
1.00
0.99
1.00
0.64
1.00
1.84
1.00
1.00
1.00
0.69
1.67

Male
Female
<1 pill per week
≥ 1 pill per week
<1 pill per week
≥ 1 pill per week
Yes
No
Yes
No
Never
Past
Current

59

95% CI

p-value

0.27-8.14
0.96-1.24

0.650
0.175

0.23-4.73

0.959

0.19-5.01

0.986

0.13-3.06

0.638

0.31-10.89

0.500

0.22-4.57

0.997

0.17-2.90
0.17-16.40

0.615
0.662

Table 15: Multivariate ORs and 95% CIs in relation to ACF Number: Age-stratified (≥50 yrs) BMI Model
Adjusted OR
Statins
Age
Sex
Baby Aspirin
All Other NSAIDs
1st Degree Relative with CRC
Personal History of Polyps
Smoking

<1 pill per week
≥ 1 pill per week

1.00
1.44
1.09
1.00
1.05
1.00
0.97
1.00
0.64
1.00
1.82
1.00
1.00
1.00
0.71
1.70
1.01

Male
Female
<1 pill per week
≥ 1 pill per week
<1 pill per week
≥ 1 pill per week
Yes
No
Yes
No
Never
Past
Current

BMI

60

95% CI

p-value

0.22-9.63
0.96-1.25

0.704
0.196

0.23-4.82

0.953

0.17-5.40

0.971

0.13-3.12

0.582

0.30-11.18

0.518

0.22-4.66

0.997

0.15-3.31
0.16-18.07
0.84-1.20

0.659
0.661
0.950

Table 16: Multivariate ORs and 95% CIs in relation to ACF Number: Age-stratified (≥50 yrs) WHR Model
Adjusted OR
Statins
Age
Sex
Baby Aspirin
All Other NSAIDs
1st Degree Relative with CRC
Personal History of Polyps
Smoking

<1 pill per week
≥ 1 pill per week

1.00
0.55
1.19
1.00
1.03
1.00
1.08
1.00
1.03
1.00
1.76
1.00
1.33
1.00
0.66
3.30
0.07

Male
Female
<1 pill per week
≥ 1 pill per week
<1 pill per week
≥ 1 pill per week
Yes
No
Yes
No
Never
Past
Current

Waist-Hip-Ratio

61

95% CI

p-value

0.06-4.80
1.00-1.41

0.591
0.054

0.19-5.53

0.970

0.17-6.77

0.935

0.19-5.64

0.976

0.27-11.5

0.554

0.21-8.21

0.762

0.10-4.44
0.25-43.07
.00-1760.30

0.670
0.363
0.600

Table 17: Multivariate ORs and 95% CIs in relation to ACF Number: Age-stratified (≥50 yrs) WC Model

Adjusted OR
Statins
Age
Sex
Baby Aspirin
All Other NSAIDs
1st Degree Relative with CRC
Personal History of Polyps
Smoking

<1 pill per week
≥ 1 pill per week

1.00
1.18
1.13
1.00
0.87
1.00
0.72
1.00
0.63
1.00
1.87
1.00
0.89
1.00
0.96
1.63
1.00

Male
Female
<1 pill per week
≥ 1 pill per week
<1 pill per week
≥ 1 pill per week
Yes
No
Yes
No
Never
Past
Current

Waist Circumference

62

95% CI

p-value

0.17-8.00
0.96-1.32

0.869
0.133

0.18-4.29

0.865

0.12-4.56

0.731

0.12-3.20

0.577

0.30-11.75

0.507

0.15-5.25

0.894

0.16-5.66
0.15-17.40
0.87-1.18

0.967
0.685
0.874

Table 18: Univariate, Age-adjusted, and Multivariate ORs and 95% CIs in relation to ACF Number: Joint Statin & Aspirin Use
Age-Adjusted1

Univariate
n
Statins &
Aspirin Use

p-value

OR (95% CI)

11.03 (1.10-111.01)
1.35 (0.41-4.47)

0.042
0.622

No Statins or Aspirin

28

1.00

Statins Only
Aspirin Only (baby or regular)

7
26

15.00 (1.55-145.23)
1.83 (0.59-5.68)

0.019
0.293

19

4.29 (1.24-14.83)

0.022

2.26 (0.54-9.48)

-

1.06 (0.99-1.13)

Statins and Aspirin (baby or regular)
Age

Crude OR (95% CI)

80

Multivariate
p-value

1.00

-

Sex

Male
39
Female
18
NSAIDs2
<1 pill per week
45
≥1 pill per week
12
1st Degree
Yes
12
Relative CRC
No
45
Personal
Yes
21
Polyp History No
36
Smoking
Never
33
Past
16
Current
8
1 See Table 10 for age-adjusted analyses for sex, NSAIDs, 1st Degree Relative with CRC, Personal Polyp History, and Smoking
2
Removing NSAIDs from the analysis did not significantly affect results.

63

OR (95% CI)

p-value

1.00
2.06 (0.12-36.25)
0.45 (0.08-2.57)

0.620
0.369

0.265

0.45 (0.04-5.53)

0.535

0.09

1.14 (1.01-1.29)

0.035

-

1.00
0.82 (0.21-3.17)
1.00
0.69 (0.15-3.11)
1.00
1.35 (0.27-6.72)
1.00
1.28 (0.30-5.51)
1.00
0.69 (0.16-2.94)
7.30 (0.87-61.65)

0.775
0.627
0.715
0.737
0.616
0.068

